| Source: TOMI Environmental Solutions, Inc.
FREDERICK, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) — TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, announced today announced it has received a significant signed purchase contract including a purchase order valued at approximately $500,000 from one of the world’s largest and most respected biopharmaceutical companies. This order is for the complete integration of TOMI’s SteraMist Integrated Systems (SIS) platform into critical manufacturing infrastructure.
The purchase contract specifically mandates the use of SteraMist iHP technology into passthrough fill boxes—a crucial component in the client’s sterile manufacturing and advanced therapeutic production process. These systems will be deployed across two separate areas in the global biopharma company specializing in the discovery, development, and manufacture of innovative medicines.
The SteraMist Integrated Systems (SIS) will provide a fully automated, rapid, and residue-free decontamination solution for both critical chambers. The scope of this contract also includes comprehensive installation and performance qualification (PQ) services delivered by TOMI’s expert technical team, ensuring the systems meet stringent biopharmaceutical regulatory requirements for validation.
The SIS platform, formally launched in late 2024, is designed to meet the escalating industry demand for automated, in-line, and high-throughput decontamination. These two projects were previously discussed as part of the $13 million pipeline for automated installation projects, underscoring the SIS platform’s effectiveness as it actively drives the pipeline. While the current order focuses on two locations, the increasing industry interest is demonstrated by the robust pipeline of orders anticipated throughout 2026 and beyond.
Elissa (E.J.) Shane, TOMI’s Chief Operating Officer, commented on the milestone: “We value the opportunity to work closely with large pharmaceutical organizations to support their critical manufacturing and sterility assurance needs. We are seeing increasing recognition among large pharmaceutical and biopharmaceutical organizations of the efficacy, material compatibility, and automation advantages of SteraMist iHP technology. In particular, the SteraMist Integrated System platform is generating exceptionally promising interest. As companies evaluate solutions that meet rigorous validation and throughput requirements, the SteraMist Integrated System directly addresses the demand for advanced automation in laboratory and manufacturing chambers.”
About TOMI™ Environmental Solutions, Inc.: Innovating for a safer world®
TOMI™ Environmental Solutions, Inc. (NASDAQ:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP™). Represented by the SteraMist® brand of products, iHP™ produces a germ-killing aerosol that works like a visual non-caustic gas.
TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences.
TOMI develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, America Seed Trade Association, and The Restoration Industry Association.
For additional information, please visit https://www.steramist.com or contact us at info@tomimist.com.
Forward-Looking Statements
This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements regarding projected pipeline and potential revenue and sales, timing for completion of SIS projects and expected financial performance in 2026. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to acquire new customers and expands sales; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.
INVESTOR RELATIONS CONTACT:
John Nesbett/Rosalyn Christian
IMS Investor Relations
tomi@imsinvestorrelations.com
